All News

FDA.approved.jpg

MTX + Pegloticase Combo FDA Approved

d Jack Cush, MD

Horizon has announced that the U.S. Food and Drug Administration (FDA) has approved the expanded labeling of pegloticase (Krystexxa) injection to be co-administered with methotrexate (MTX), to improve response rates in patients with uncontrolled gout.

Read Article
Allopurinol Safety in CKD Patients A study in the Annals of Internal Medicine reports chronic kidney disease (CKD) patients can be safely treated with allopurinol without an increased risk of mortality. https://t.co/qUQmuZedJq https://t.co/u2Ntjd1oio

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

What Worries You, Masters You (7.1.2022)

d Jack Cush, MD

Dr. Jack Cush reviews recent news, regulatory and guideline updates from the past week on RheumNow.com.  Studies on methotrexate use, COVID vaccination, Supplements and vitamins, and arthrocentesis despite anticoagulation are discussed.

Read Article
Renal Tubular Disorders #NephTwitter #MedEd #MedDoodles https://t.co/KiCuEaDGrR
Sarah Lyon sarahthelyon ( View Tweet)
FDA approved Abbvies risakizumab-rzaa (Skyrizi) as the 1st interleukin-23 inhibitor for use in adults with moderately to severely active Crohn's disease (600 mg IV at wk 0, 4, 8, &q8wk @ 360 mg SC). Approval based on ADVANCE, MOTIVATE & FORTIFY RCTs https://t.co/OMYNB1yr2R https://t.co/QMn9GWlYm9

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA approved Abbvies risakizumab-rzaa (Skyrizi) as the 1st interleukin-23 inhibitor for use in adults with moderately to severely active Crohn's disease (600 mg IV at wk 0, 4, 8, &q8wk @ 360 mg SC). Approval based on ADVANCE, MOTIVATE & FORTIFY RCTs https://t.co/Y6FVcjHGr2 https://t.co/eTYedqiScE

Links:

Dr. John Cush RheumNow ( View Tweet)
JAK Janus

JAK/STAT pathway in pyoderma gangrenosum: a new therapeutic highway?

d Aurelie Najm, MD, PhD

Pyoderma gangrenosum (PG) is rare, but often associated with different forms of arthritis, in particular rheumatoid arthritis and inflammatory bowel diseases. 

Read Article
Gut microbiome of AS patients different from healthy controls. Different bacteria communities may be associated with disease activity. So much more to digest.... @RheumNow #EULAR2022 ABST#POS0330 https://t.co/EAvHngd6SD
Robert B Chao, MD doctorRBC ( View Tweet)
Does diet drive IL-23 in IBD and PsA? Perhaps if you have the right baseline risk. The science is evolving quickly Stronger rationale that diet may be really important in some patients #EULAR2022 #IL23 @RheumNow https://t.co/hV54PvfOXV
David Liew drdavidliew ( View Tweet)
#EULAR2022 OP0071 Association between long-term exposure to air pollution (fine particulate matter) and immune-mediated disease in Italy ⭐️⬆️ risk of autoimmune disease, esp RA as well as CTD, IBD ⭐️Every 10 ug/m3 increase in PM, associated with incremental 7% risk @RheumNow https://t.co/x57CXUHSHb
Eric Dein ericdeinmd ( View Tweet)
Watch: Lupus Nephritis: The Blind Men and the Kidney with Dr. Joan Merrill Joan Merrill discusses treatment of lupus nephritis. This was previously recorded at RheumNow Live 2022. https://t.co/9GRw5VGTKr https://t.co/PS6aEk1fsx

Links:

Dr. John Cush RheumNow ( View Tweet)
child.guttate.psoriasis

Psoriasis and Nonalcoholic Fatty Liver Disease

d Jack Cush, MD

A large US population based study shows that psoriasis is associated with a higher risk of nonalcoholic fatty liver disease (NAFLD).

Read Article
RheumNow Podcast square

The Inflammation Reflex (5.20.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, neuroimmunology leading to therapy, the cold shoulder approach and Regulatory updates from the FDA.

Read Article
SpA,RNL,2022

RNL 2022: Spondyloarthritis Spectrum

d Jack Cush, MD

This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.



- Microbiome in Spondyloathritis - Jose Scher, MD



- Axial Psoriatic Arthritis - Philip Mease, MD



- Juvenile Spondyloathritis - Pamela Weiss, MD


Read Article
Early results from the U-ENDURE, Phase 3 RCT of upadacitinib in adult Crohns disease. Pts responding to UPA 45 mg/d were given PBO or UPA (15 or 30 mg). 52 wk UPA achieved CDAI (37% & 48% vs 15% PBO)& endoscopic remission (28% & 40% vs 7%) https://t.co/eo2KtNOUW8 https://t.co/MKnTxVEkth

Links:

Dr. John Cush RheumNow ( View Tweet)
Our response to statins is influenced by our gut microbiome https://t.co/xKZdxO13va New @MedCellPress https://t.co/BxwhRhMAX9

Links:

Eric Topol EricTopol ( View Tweet)
GALAXI-1 Study - Guselkumab effective in Crohn's Disease. 309 CD pts (1/2 refractory dz) Rx w/ either PBO, or IV GUS 200 mg, 600 mg, or 1200 mg at weeks 0, 4, and 8; At week 12, all 3 doses had signif. clinical and endoscopic improvements vs PBO https://t.co/iGyAmCoO96

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast square

$30 Billion and Counting (4.29.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports and takes viewer questions this week.

Read Article
Study of PCP Dx irritable bowel dz; 459 randomised to 8 weeks of oral antispasmodics or diet (low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP). Better responses with diet (71% vs 61%; p=0.03). Better adherence w/ diet. https://t.co/gmn45yQmuB https://t.co/8SP5Vfx71z

Links:

Dr. John Cush RheumNow ( View Tweet)
TNRPSA,0426

PsA Journal Club - Fecal Transplant & H2H IXE vs ADA

d Jack Cush, MD

Playback now available! Watch our Tuesday Nite Rheumatology, held April 26th, 2022, which featured a Journal Club panel discussion  about two important studies.

Read Article

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.